These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 7909557)

  • 1. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
    Shannon HE; Bymaster FP; Calligaro DO; Greenwood B; Mitch CH; Sawyer BD; Ward JS; Wong DT; Olesen PH; Sheardown MJ; Swedberg MD; Suzdak PD; Sauerberg P
    J Pharmacol Exp Ther; 1994 Apr; 269(1):271-81. PubMed ID: 7909557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).
    Bymaster FP; Wong DT; Mitch CH; Ward JS; Calligaro DO; Schoepp DD; Shannon HE; Sheardown MJ; Olesen PH; Suzdak PD; Swedberg MD; Sauerberg P
    J Pharmacol Exp Ther; 1994 Apr; 269(1):282-9. PubMed ID: 7909558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of butylthio[2.2.2] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activity.
    Shannon HE; Sheardown MJ; Bymaster FP; Calligaro DO; Delapp NW; Gidda J; Mitch CH; Sawyer BD; Stengel PW; Ward JS; Wong DT; Olesen PH; Suzdak PD; Sauerberg P; Swedberg MD
    J Pharmacol Exp Ther; 1997 May; 281(2):884-94. PubMed ID: 9152398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. M1 receptor agonist activity is not a requirement for muscarinic antinociception.
    Sheardown MJ; Shannon HE; Swedberg MD; Suzdak PD; Bymaster FP; Olesen PH; Mitch CH; Ward JS; Sauerberg P
    J Pharmacol Exp Ther; 1997 May; 281(2):868-75. PubMed ID: 9152396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
    Watson J; Brough S; Coldwell MC; Gager T; Ho M; Hunter AJ; Jerman J; Middlemiss DN; Riley GJ; Brown AM
    Br J Pharmacol; 1998 Dec; 125(7):1413-20. PubMed ID: 9884068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .
    Sauerberg P; Olesen PH; Nielsen S; Treppendahl S; Sheardown MJ; Honoré T; Mitch CH; Ward JS; Pike AJ; Bymaster FP
    J Med Chem; 1992 Jun; 35(12):2274-83. PubMed ID: 1613751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor.
    Christopoulos A; Parsons AM; El-Fakahany EE
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1220-8. PubMed ID: 10336509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterisation of the enantiomers of BM-5, a muscarinic partial agonist with opposed enantioselectivity between affinity and efficacy.
    Sundquist S; Modiri AR; Nilsson BM; Hacksell U; Gillberg PG; Nilvebrant L
    Pharmacol Toxicol; 2000 Jan; 86(1):44-50. PubMed ID: 10720106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain.
    Machová E; Jakubík J; El-Fakahany EE; Dolezal V
    J Pharmacol Exp Ther; 2007 Jul; 322(1):316-23. PubMed ID: 17446301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects.
    Bymaster FP; Carter PA; Peters SC; Zhang W; Ward JS; Mitch CH; Calligaro DO; Whitesitt CA; DeLapp N; Shannon HE; Rimvall K; Jeppesen L; Sheardown MJ; Fink-Jensen A; Sauerberg P
    Brain Res; 1998 Jun; 795(1-2):179-90. PubMed ID: 9622623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.
    Stengel PW; Cohen ML
    J Pharmacol Exp Ther; 2001 Mar; 296(3):818-24. PubMed ID: 11181912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct functional muscarinic receptors in guinea-pig gallbladder, ileum and atria.
    Karaalp A; Akici A; Akbulut H; Ulusoy NB; Oktay S
    Pharmacol Res; 1999 May; 39(5):389-95. PubMed ID: 10328997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.
    Hirose H; Aoki I; Kimura T; Fujikawa T; Numazawa T; Sasaki K; Sato A; Hasegawa T; Nishikibe M; Mitsuya M; Ohtake N; Mase T; Noguchi K
    J Pharmacol Exp Ther; 2001 May; 297(2):790-7. PubMed ID: 11303071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the muscarinic receptor subtype(s) mediating contraction of the guinea-pig lung strip and inhibition of acetylcholine release in the guinea-pig trachea with the selective muscarinic receptor antagonist tripitramine.
    Roffel AF; Davids JH; Elzinga CR; Wolf D; Zaagsma J; Kilbinger H
    Br J Pharmacol; 1997 Sep; 122(1):133-41. PubMed ID: 9298539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland.
    Kobayashi F; Yageta Y; Segawa M; Matsuzawa S
    Arzneimittelforschung; 2007; 57(2):92-100. PubMed ID: 17396619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (+/-)-Terodiline: an M1-selective muscarinic receptor antagonist. In vivo effects at muscarinic receptors mediating urinary bladder contraction, mydriasis and salivary secretion.
    Noronha-Blob L; Prosser JC; Sturm BL; Lowe VC; Enna SJ
    Eur J Pharmacol; 1991 Aug; 201(2-3):135-42. PubMed ID: 1724648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel functional M1 selective muscarinic agonists. 2. Synthesis and structure-activity relationships of 3-pyrazinyl-1,2,5,6-tetrahydro-1-methylpyridines. Construction of a molecular model for the M1 pharmacophore.
    Ward JS; Merritt L; Klimkowski VJ; Lamb ML; Mitch CH; Bymaster FP; Sawyer B; Shannon HE; Olesen PH; Honoré T
    J Med Chem; 1992 Oct; 35(22):4011-9. PubMed ID: 1433209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscarinic M1 receptor agonist actions of muscarinic receptor agonists in rabbit vas deferens.
    Shannon HE; Sawyer BD; Bemis KG; Bymaster FP; Health I; Mitch CH; Ward JS
    Eur J Pharmacol; 1993 Feb; 232(1):47-57. PubMed ID: 8458395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor.
    Grant MK; El-Fakahany EE
    J Pharmacol Exp Ther; 2005 Oct; 315(1):313-9. PubMed ID: 16002459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New analogues of oxotremorine and oxotremorine-M: estimation of their in vitro affinity and efficacy at muscarinic receptor subtypes.
    Barocelli E; Ballabeni V; Bertoni S; Dallanoce C; De Amici M; De Micheli C; Impicciatore M
    Life Sci; 2000 Jun; 67(6):717-23. PubMed ID: 12659177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.